Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.46 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6849222 | 0.85 | MEN1 (0.71) | MEN1KMT2AALDH1A1GAAPKM | |
| SCHEMBL29627490 | 0.85 | MEN1 (0.61) | MEN1KMT2AALDH1A1GAAPKM | |
| SCHEMBL70297 | 0.85 | MEN1 (0.61) | MEN1KMT2AALDH1A1GAAPKM | |
| SCHEMBL112949 | 0.81 | MEN1 (0.58) | MEN1KMT2AALDH1A1GAAPKM | |
| SCHEMBL4988971 | 0.81 | SMN1; SMN2 (0.61) | MEN1KMT2AALDH1A1GAAPKM | |
| SCHEMBL795882 | 0.81 | MEN1 (0.62) | MEN1KMT2AALDH1A1GAAPKM | |
| SCHEMBL6967207 | 0.81 | MEN1 (0.58) | MEN1KMT2AALDH1A1GAAPKM | |
| SCHEMBL1763611 | 0.81 | MEN1 (0.58) | MEN1KMT2AALDH1A1GAAPKM | |
| SCHEMBL70296 | 0.81 | MEN1 (0.58) | MEN1KMT2AALDH1A1GAAPKM | |
| SCHEMBL29938229 | 0.81 | MEN1 (0.58) | MEN1KMT2AALDH1A1GAAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200148764-A1 | CROSS-LINKERS AND THEIR USES | IMMUNOGEN, INC. | 2020-05-14 | — | — | US | claimed |
| US-20180291100-A1 | CROSS-LINKERS AND THEIR USES | IMMUNOGEN SWITZERLAND GMBH (CH) | 2018-10-11 | — | — | US | claimed |
| EP-2281006-B1 | CROSS-LINKERS AND THEIR USES | IMMUNOGEN INC (US) | 2017-08-02 | — | — | EP | claimed |
| US-8236319-B2 | Cross-linkers and their uses | IMMUNOGEN, INC. (US) | 2012-08-07 | — | — | US | claimed |
| EP-1601373-A4 | INTRACELLULAR DELIVERY OF SMALL MOLECULES PROTEINS AND NUCLEIC ACIDS | BIOWHITTAKER TECHNOLOGIES INC (US) | 2007-07-11 | — | — | EP | claimed |
| US-7166692-B2 | Intracellular delivery of small molecules, proteins, and nucleic acids | CANBREX BIO SCIENCE WALKERSVILLE, INC. (US) | 2007-01-23 | — | — | US | claimed |
| US-20060106197-A1 | Intracellular delivery of small molecules, proteins, and nucleic acids | LONZA BIOSCIENCE TECHNOLOGIES, INC. | 2006-05-18 | — | — | US | claimed |
| EP-1601373-A2 | INTRACELLULAR DELIVERY OF SMALL MOLECULES PROTEINS AND NUCLEIC ACIDS | Biowhittaker Technologies, Inc. (US) | 2005-12-07 | — | — | EP | claimed |
| US-20040209797-A1 | Intracellular delivery of small molecules, proteins, and nucleic acids | LONZA WALKERSVILLE INC. | 2004-10-21 | — | — | US | claimed |
| WO-2004078933-A2 | INTRACELLULAR DELIVERY OF SMALL MOLECULES PROTEINS AND NUCLEIC ACIDS | BIOWHITTAKER TECHNOLOGIES INC. (US) | 2004-09-16 | — | — | WO | claimed |
| EP-4242220-A1 | PEPTIDE CROSSLINKING AGENT AND CROSSLINKED PEPTIDE WHICH IS CROSSLINKED USING SAID CROSSLINKING AGENT | Kagoshima University (JP) | 2023-09-13 | — | — | EP | disclosed |
| US-20210312797-A9 | PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF | ABBVIE INC (US) | 2021-10-07 | — | — | US | disclosed |
| CN-107090034-B | M-CSF specific monoclonal antibody and application thereof | 诺华疫苗和诊断公司 | 2021-10-01 | — | — | CN | disclosed |
| EP-3851126-A1 | MAYTANSINOID-CELL-BINDING AGENT CONJUGATES | ImmunoGen, Inc. (US) | 2021-07-21 | — | — | EP | disclosed |
| US-11046762-B2 | Cross-linkers and their uses | IMMUNOGEN, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20040039176-A1 | Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs | IMMUNOGEN, INC. | 2004-02-26 | — | — | US | disclosed |
| WO-2004016801-A2 | CROSS-LINKERS WITH HIGH REACTIVITY AND SOLUBILITY AND THEIR USE IN THE PREPARATION OF CONJUGATES FOR TARGETED DELIVERY OF SMALL MOLECULE DRUGS | IMMUNOGEN, INC. (US) | 2004-02-26 | — | — | WO | disclosed |
| US-20030212011-A1 | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2003-11-13 | — | — | US | disclosed |
| WO-2003072588-A1 | MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2003-09-04 | — | — | WO | disclosed |
| US-4866180-A | MITOMYCIN ANALOGS; ANTITUMOR AGENTS | BRISTOL-MYERS COMPANY (US) | 1989-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212011-A1 | Macrolides with antibacterial activity | MRPL21, RPS21, MRPS18A | MEN1 1793/4885KMT2A 3930/4885ALDH1A1 3345/4885 |
| US-20180291100-A1 | CROSS-LINKERS AND THEIR USES | MTCL3, DCLRE1A, PCNA | MEN1 3140/4885KMT2A 3217/4885ALDH1A1 3130/4885 |
| US-20200148764-A1 | CROSS-LINKERS AND THEIR USES | MTCL3, DCLRE1A, PCNA | MEN1 3140/4885KMT2A 3217/4885ALDH1A1 3130/4885 |
| US-11046762-B2 | Cross-linkers and their uses | MTCL3, DCLRE1A, PCNA | MEN1 3140/4885KMT2A 3217/4885ALDH1A1 3130/4885 |
| US-20040039176-A1 | Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs | CD44, ABCG2, EPCAM | MEN1 4531/4885KMT2A 3717/4885ALDH1A1 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.